CHARMANT Group competitors

Patrick A. McBrayerPresident and Chief Executive Officer[email protected]215-530-0503Patrick McBrayer is President & CEO of ACell Inc. ACell is a leading regenerative medicine company focused on the development, manufacturing and commercialization of unique proprietary extracellular matrix (ECM) products to facilitate the repair and remodeling of damaged tissues (www.acell.com). He is also on the Board of Directors of Misonix Inc (NASDAQ:MSON), which markets therapeutic ultrasound medical devices world-wide.Mr. McBrayer was President and Chief Executive Officer of AxioMed™ Spine Corporation of Garfield Heights, Ohio until the company was acquired in 2014. AxioMed is a medical device company focused on restoring the native function of the spine. The company’s Freedom total disc spine technology is commercially available in the EU and is in PMA clinical trials in the United States.Prior to AxioMed, Mr. McBrayer was Chief Executive Officer of Xylos Corporation, a medical biomaterials company. He is also a Founder of Transave Inc. (now Insmed Inc.), a biotechnology company focused on the site specific treatment of lung disease. Prior to joining Xylos, Mr. McBrayer served as President and CEO of Exogen, Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew, Inc. in 1999. Previously, Mr. McBrayer was President and CEO of Osteotech, Inc., a worldwide leader in tissue technology (acquired by Medtronic Inc.). In both companies he was responsible for a number of private placements and both companies’ public offerings and led these organizations to dominant market share positions. He received the Thomas Alva Edison Patent Award in 1998 for a biological implant for bone repair that is now a market leading product. Prior to joining Osteotech, Mr. McBrayer held positions of increasing responsibility for Johnson & Johnson, Inc.